• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Gabapentinoids unlikely to be directly linked to self-harm risk, study finds

April 30, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
patient
6
SHARES
14
VIEWS
Share on FacebookShare on Twitter


patient
Credit: CC0 Public Domain

Treatment with gabapentinoids—drugs such as gabapentin and pregabalin—is not directly associated with an increased risk of self-harm, finds a UK study published by The BMJ.

However, rates of self-harm were higher before and shortly after treatment, highlighting the need for close monitoring of patients throughout their treatment journey, say the researchers.

Gabapentinoids are prescribed for conditions such as epilepsy, nerve pain, and anxiety disorders.

Previous studies have raised concerns about potential side effects, including an increased risk of self-harm, but did not examine the risks immediately before starting or after stopping gabapentinoids, despite the fact that these drugs may be prescribed for conditions associated with self-harm. As such, the nature of this relationship is still not fully understood.

To obtain a clearer picture, researchers analyzed electronic health records of 10,002 individuals in the UK aged 18 and over (average age 39; 67% female) who were prescribed gabapentinoids between 2000 and 2020 and had at least one hospital record of self-harm.

They examined rates of self-harm in four distinct time periods for each individual—90 days before starting treatment, the treatment period, the 14 days after stopping treatment, and any other period, which acted as the reference category.

By comparing each individual with themselves across time, the researchers were able to account for all potential confounding factors, including genetic risks, childhood environment and early-onset conditions. They also accounted for age, seasonality, and other prescribed opioid and psychotropic medications.

Of the 10,002 individuals, 4,767 (48%) took gabapentin only, 3,164 (32%) took pregabalin only and 2,071 (21%) took both over an average follow-up period of 13 years.

Compared with the reference period, the rate of self-harm increased by 69% (16.8 per 100 person years) in the 90 days leading up to the start of treatment, suggesting that individuals prescribed these drugs may already be at an increased risk.

This risk declined during the treatment period, but markedly increased to 29.6 per 100 person years in the two-week period after treatment had ended, before returning to reference levels, suggesting that gabapentinoids are unlikely to be linked to self-harm risk.

The researchers acknowledge that these are observational findings and results may be limited by the small sample sizes within some groups. What’s more, they were only able to capture prescriptions issued by a general practitioner and cases of self-harm severe enough to be admitted to hospital.

Nevertheless, their use of a large population-based database provided sufficient statistical power to evaluate the association between gabapentinoid use and self-harm, and the results were similar after further analyses, suggesting they are robust.

This study provides valuable insights into the association between gabapentinoid treatment and self-harm risks, they write. And while further studies are needed in different populations, they say these findings “underscore the necessity for close patient monitoring of self-harm throughout the gabapentinoid treatment journey.”

This investigation shows the importance of testing associations in primary and secondary care, and the authors’ novel approach of considering periods before and after treatment is an important contribution, note the researchers in a linked editorial.

They point to some important study limitations, but acknowledge that, “clinically, their results suggest that routine and periodic follow-up of people prescribed gabapentinoids should be considered, particularly in the weeks after medication has been discontinued.”

They add, “Whether young adults and people with no psychiatric diagnoses need more supervision while taking gabapentinoids requires further research to clarify.”

More information:
Association of gabapentinoid treatment and the risk of self-harm: self-controlled, population based case series, The BMJ (2025). DOI: 10.1136/bmj-2024-081627

Provided by
British Medical Journal


Citation:
Gabapentinoids unlikely to be directly linked to self-harm risk, study finds (2025, April 30)
retrieved 30 April 2025
from https://medicalxpress.com/news/2025-04-gabapentinoids-linked.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



patient
Credit: CC0 Public Domain

Treatment with gabapentinoids—drugs such as gabapentin and pregabalin—is not directly associated with an increased risk of self-harm, finds a UK study published by The BMJ.

However, rates of self-harm were higher before and shortly after treatment, highlighting the need for close monitoring of patients throughout their treatment journey, say the researchers.

Gabapentinoids are prescribed for conditions such as epilepsy, nerve pain, and anxiety disorders.

Previous studies have raised concerns about potential side effects, including an increased risk of self-harm, but did not examine the risks immediately before starting or after stopping gabapentinoids, despite the fact that these drugs may be prescribed for conditions associated with self-harm. As such, the nature of this relationship is still not fully understood.

To obtain a clearer picture, researchers analyzed electronic health records of 10,002 individuals in the UK aged 18 and over (average age 39; 67% female) who were prescribed gabapentinoids between 2000 and 2020 and had at least one hospital record of self-harm.

They examined rates of self-harm in four distinct time periods for each individual—90 days before starting treatment, the treatment period, the 14 days after stopping treatment, and any other period, which acted as the reference category.

By comparing each individual with themselves across time, the researchers were able to account for all potential confounding factors, including genetic risks, childhood environment and early-onset conditions. They also accounted for age, seasonality, and other prescribed opioid and psychotropic medications.

Of the 10,002 individuals, 4,767 (48%) took gabapentin only, 3,164 (32%) took pregabalin only and 2,071 (21%) took both over an average follow-up period of 13 years.

Compared with the reference period, the rate of self-harm increased by 69% (16.8 per 100 person years) in the 90 days leading up to the start of treatment, suggesting that individuals prescribed these drugs may already be at an increased risk.

This risk declined during the treatment period, but markedly increased to 29.6 per 100 person years in the two-week period after treatment had ended, before returning to reference levels, suggesting that gabapentinoids are unlikely to be linked to self-harm risk.

The researchers acknowledge that these are observational findings and results may be limited by the small sample sizes within some groups. What’s more, they were only able to capture prescriptions issued by a general practitioner and cases of self-harm severe enough to be admitted to hospital.

Nevertheless, their use of a large population-based database provided sufficient statistical power to evaluate the association between gabapentinoid use and self-harm, and the results were similar after further analyses, suggesting they are robust.

This study provides valuable insights into the association between gabapentinoid treatment and self-harm risks, they write. And while further studies are needed in different populations, they say these findings “underscore the necessity for close patient monitoring of self-harm throughout the gabapentinoid treatment journey.”

This investigation shows the importance of testing associations in primary and secondary care, and the authors’ novel approach of considering periods before and after treatment is an important contribution, note the researchers in a linked editorial.

They point to some important study limitations, but acknowledge that, “clinically, their results suggest that routine and periodic follow-up of people prescribed gabapentinoids should be considered, particularly in the weeks after medication has been discontinued.”

They add, “Whether young adults and people with no psychiatric diagnoses need more supervision while taking gabapentinoids requires further research to clarify.”

More information:
Association of gabapentinoid treatment and the risk of self-harm: self-controlled, population based case series, The BMJ (2025). DOI: 10.1136/bmj-2024-081627

Provided by
British Medical Journal


Citation:
Gabapentinoids unlikely to be directly linked to self-harm risk, study finds (2025, April 30)
retrieved 30 April 2025
from https://medicalxpress.com/news/2025-04-gabapentinoids-linked.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Student allegedly discharges ‘possible firearm’ in Marina del Rey classroom

Next Post

How a circular economy for ageing wind turbines can make repowering a sustainable option  

Related Posts

disability

Experimental drug may benefit some patients with rare form of ALS

May 22, 2025
0
WellTheory raises $5M for AI-enabled autoimmune care platform

WellTheory raises $5M for AI-enabled autoimmune care platform

May 22, 2025
9
Next Post
Workers in an outdoor facility surrounded by large circular panels, which are components from wind energy systems

How a circular economy for ageing wind turbines can make repowering a sustainable option  

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Bureau of Land Management releases arctic lease sale analysis

House votes to take away clean energy tax credits

May 22, 2025
disability

Experimental drug may benefit some patients with rare form of ALS

May 22, 2025
Thousands of chicks found abandoned in USPS truck have been adopted

Thousands of chicks found abandoned in USPS truck have been adopted

May 22, 2025
DC Capital Jewish Museum shooting: Two awful truths about the murders

DC Capital Jewish Museum shooting: Two awful truths about the murders

May 22, 2025

Recent News

Bureau of Land Management releases arctic lease sale analysis

House votes to take away clean energy tax credits

May 22, 2025
0
disability

Experimental drug may benefit some patients with rare form of ALS

May 22, 2025
0
Thousands of chicks found abandoned in USPS truck have been adopted

Thousands of chicks found abandoned in USPS truck have been adopted

May 22, 2025
2
DC Capital Jewish Museum shooting: Two awful truths about the murders

DC Capital Jewish Museum shooting: Two awful truths about the murders

May 22, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Bureau of Land Management releases arctic lease sale analysis

House votes to take away clean energy tax credits

May 22, 2025
disability

Experimental drug may benefit some patients with rare form of ALS

May 22, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co